Novel Biomarker Identification

The identification and use of predictive biomarker assays has become an integral part of the drug discovery and development process. Charles River has broad expertise in biomarker identification and assay development across a range of therapeutic areas, including respiratory disease, oncology, CNS and metabolic diseases.

Capabilities span the identification and validation of biomarkers and the development of quantitative assays in primary cells and disease tissue, pharmacodynamic and disease models, and as efficacy and translational medicine markers in the clinic. Our experience includes the translation of biomarker assays for use in the clinic for several client projects.

Webinar Replay

View this webinar for insight into the drug discovery process within pharma and biotech with a focus on target engagement biomarkers. View Now »

  • Proteomic markers
  • Genomic markers
  • Phosphoprotein markers
  • Epigenetic markers
  • MesoScale for multiplexed immunoassay endpoints
  • FACS analysis
  • Mass spectrometry

You may also be interested in...

Translational Tools

Translational Tools

Our translational tools have been shown to dramatically increase the efficiency of lead candidate selection by providing earlier and more highly predictive data.

lab tech conducting biological sample processing in a hood

Integrated Drug Discovery

We operate as a proactive thinking partner bringing target to clinical candidate capabilities, ideas and solutions to your program.